675 related articles for article (PubMed ID: 30341008)
1. Application of induced pluripotent stem cell technology for the investigation of hematological disorders.
Dolatshad H; Tatwavedi D; Ahmed D; Tegethoff JF; Boultwood J; Pellagatti A
Adv Biol Regul; 2019 Jan; 71():19-33. PubMed ID: 30341008
[TBL] [Abstract][Full Text] [Related]
2. Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells.
Kim H; Schaniel C
Front Immunol; 2018; 9():2243. PubMed ID: 30323816
[TBL] [Abstract][Full Text] [Related]
3. Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications.
Elbadry MI; Espinoza JL; Nakao S
Exp Hematol; 2017 May; 49():9-18. PubMed ID: 28062362
[TBL] [Abstract][Full Text] [Related]
4. Induced pluripotent stem cells and hematological malignancies: A powerful tool for disease modeling and drug development.
Donada A; Basso-Valentina F; Arkoun B; Monte-Mor B; Plo I; Raslova H
Stem Cell Res; 2020 Dec; 49():102060. PubMed ID: 33142254
[TBL] [Abstract][Full Text] [Related]
5. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
Liu Y; Deng W
Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
[TBL] [Abstract][Full Text] [Related]
6. Modeling blood diseases with human induced pluripotent stem cells.
Georgomanoli M; Papapetrou EP
Dis Model Mech; 2019 Jun; 12(6):. PubMed ID: 31171568
[TBL] [Abstract][Full Text] [Related]
7. Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders.
Wattanapanitch M
Stem Cells Int; 2019; 2019():5171032. PubMed ID: 31191673
[TBL] [Abstract][Full Text] [Related]
8. [Application of iPS cells derived from congenital myelodysplastic syndrome for research of nomal hematopoesis and hematological malignancies].
Nakajima H
Rinsho Ketsueki; 2016 Aug; 57(8):1087-94. PubMed ID: 27599428
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the Power of Induced Pluripotent Stem Cells and Gene Editing Technology: Therapeutic Implications in Hematological Malignancies.
Sidhu I; Barwe SP; Pillai RK; Gopalakrishnapillai A
Cells; 2021 Oct; 10(10):. PubMed ID: 34685678
[TBL] [Abstract][Full Text] [Related]
10. Gene correction in patient-specific iPSCs for therapy development and disease modeling.
Jang YY; Ye Z
Hum Genet; 2016 Sep; 135(9):1041-58. PubMed ID: 27256364
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic defects and iPSC disease modeling: lessons learned.
Kelley JM; Daley GQ
Immunol Lett; 2013; 155(1-2):18-20. PubMed ID: 24076116
[TBL] [Abstract][Full Text] [Related]
12. Modeling of hematologic malignancies by iPS technology.
Arai S; Miyauchi M; Kurokawa M
Exp Hematol; 2015 Aug; 43(8):654-60. PubMed ID: 26135030
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies.
Tatwavedi D; Pellagatti A; Boultwood J
Adv Biol Regul; 2024 Jan; 91():100993. PubMed ID: 37827894
[TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cell modeling of malignant hematopoiesis.
Chao MP; Majeti R
Exp Hematol; 2019 Mar; 71():68-76. PubMed ID: 30659850
[TBL] [Abstract][Full Text] [Related]
15. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9.
Ben Jehuda R; Shemer Y; Binah O
Stem Cell Rev Rep; 2018 Jun; 14(3):323-336. PubMed ID: 29623532
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases.
Hung SSC; Khan S; Lo CY; Hewitt AW; Wong RCB
Pharmacol Ther; 2017 Sep; 177():32-43. PubMed ID: 28223228
[TBL] [Abstract][Full Text] [Related]
17. Promise and challenges of human iPSC-based hematologic disease modeling and treatment.
Ye Z; Chou BK; Cheng L
Int J Hematol; 2012 Jun; 95(6):601-9. PubMed ID: 22619021
[TBL] [Abstract][Full Text] [Related]
18. Pluripotent stem cell based gene therapy for hematological diseases.
Vanhee S; Vandekerckhove B
Crit Rev Oncol Hematol; 2016 Jan; 97():238-46. PubMed ID: 26381313
[TBL] [Abstract][Full Text] [Related]
19. [Induced pluripotent stem cell technology and its application in disease research].
Cai CY; Meng FL; Rao L; Liu YY; Zhao XL
Yi Chuan; 2020 Nov; 42(11):1042-1061. PubMed ID: 33229312
[TBL] [Abstract][Full Text] [Related]
20. Generation and genetic modification of induced pluripotent stem cells.
Schambach A; Cantz T; Baum C; Cathomen T
Expert Opin Biol Ther; 2010 Jul; 10(7):1089-103. PubMed ID: 20528610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
